Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Korosho Taking Public Comments on Proposed GL for Development of Prototype Pandemic Flu Vaccines
August 15, 2011
- RaQualia of Japan Aims to Become Global Drug Discovery Innovator
August 15, 2011
- Santen Creates Subsidiary in India
August 15, 2011
- Korosho Announces Revised Precautions for Diabetes Treatment Metgluco
August 15, 2011
- TOPICS 2 articles
August 15, 2011
- System to Ensure Early Price Settlement Necessary: Non-Partisan Council of Diet Members
August 15, 2011
- Dissolution Test Methods Annexed to ICH Q4B GLs Go into Effect
August 15, 2011
- Taisho Completes Acquisition of Malaysian Company
August 15, 2011
- EPS: Sales Up, Profits Down due to Slump of CRO Business
August 15, 2011
- JPO's WG to Resume Discussions to Revise Patent Term Extension Rule for DDS Preparations
August 15, 2011
- Asahi Kasei to Make Asahi Kasei Kuraray Medical a Wholly-owned Subsidiary
August 15, 2011
- Qol Opens Dispensing Pharmacy at Major Electronics Retail Store
August 15, 2011
- Nichi-Iko to Strengthen Relationships with Wholesalers
August 15, 2011
- NCVC to Expand Infrastructure for 1st-in-human Studies for Medical Devices
August 15, 2011
- FIRM Starts Activities Creating 3 WGs
August 15, 2011
- Daiichi Sankyo to Expand Hybrid Business Model in Mexico
August 15, 2011
- Combination Drugs Are Part of Innovation: Prof. Kaku of Kawasaki Medical School
August 15, 2011
- Statistics
August 15, 2011
- DSP Not Planning Full-scale Entry into Generic Business: President Tada
August 15, 2011
- Korosho Forecasts 92,000 Patients Admitted for Dementia in 2026
August 15, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…